Good morning. My name is Emma, I will be your conference operator today. At this time, I would like to welcome everyone to the Donaldson Company Inc. Q3 2023 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star followed by one on your telephone keypad. If you would like to withdraw your question, again, press the star one. Thank you. Sarika Dhadwal, Senior Director of Investor Relations, you may begin your conference. Good morning. Thank you for joining Donaldson's Q3 Fiscal 2023 Earnings Conference Call. With me today are Tod Carpenter, Chairman, CEO, and President, and Scott Robinson, Chief Financial Officer. This morning, Tod and Scott will provide a summary of our Q3 performance and an update on our outlook for fiscal 2023. During today's call, we will discuss non-GAAP or adjusted results. A reconciliation of GAAP to non-GAAP metrics is provided within the schedules attached to this morning's press release. Additionally, please keep in mind that any forward-looking statements made during this call are subject to risks and uncertainties, which are described in our press release and SEC filings. With that, I'll now turn the call over to Tod Carpenter. Please go ahead. Thanks, Sarika. Good morning. Q3 was another record quarter for Donaldson Company. We continued the trends seen in the first half of this fiscal year. Compared with prior year, we grew our top line to a quarterly record, expanded both gross and operating margins over 100 basis points, delivered double-digit earnings growth, and produced cash conversion of approximately 105%. Before diving deeper into the quarterly results, I would like to express how pleased we were to have had so many of you participate, either in person or virtually, at our Investor Day in April. It was a big day for our company, and I will recap some key takeaways. We demonstrated our leadership position and strategy across all three segments that together drives our expectation to achieve sales of approximately $4 billion and operating margins in the 16% range by fiscal 2026. More specifically, I would like to highlight our new Life Sciences segment, where there are significant, compelling opportunities driven by organic and inorganic investments, including the recent acquisitions of Solaris, Purilogics, and Isolere Bio. These businesses, combined with Donaldson's technologies and expertise, provide a portfolio of opportunities across several end markets, such as food and beverage, alternative proteins, bioprocessing, and medical devices. Focusing in on bioprocessing, for example, we see game-changing opportunities to support the development of vaccine and advanced cell and gene therapies with our newly acquired technologies. Traditional chromatography systems are slow and not optimized for larger molecules such as mRNA and plasmid DNA. Purilogics's innovative technology provides faster flow rates and puts less stress on cells, and Isolere Bio allows us to introduce breakthrough technology that provides purification in solutions with no size limitations. Together, and combined with Donaldson's capabilities, we are at the cusp of driving scale across vaccine and cell and gene therapies to solve the world's greatest health risks. To that end, we will continue to grow these businesses by investing organically and pursuing strategic M&A in adjacent areas, which will further us on the path of continuing to create value for all of our stakeholders. Now, some Q3 highlights. Sales were up 3% year-over-year, driven by pricing of 8% and partially offset by a currency translation headwind of approximately 3%. Volume was down in the quarter as our aftermarket business was negatively impacted from OE customers continuing to reduce inventories as service levels normalize. Also, negatively impacting volumes was our disk drive business, which remains muted from market-related weakness. EPS was $0.76, a 14% increase over the prior year. Our strategic pricing, implemented to offset elevated input costs, continues to be a big driver of our quarterly sales and earnings results. Most input costs have stabilized at higher levels. Some areas, such as labor, remain a headwind. Pricing remains critical in our recovery from this period of sharp year-over-year inflation. Turning to our operations, I'm pleased by our improvements in fill rates, on-time deliveries, and late backlog levels across the organization. We are working to meet the needs of our customers today while investing in capacity projects, including in North America, to meet the needs of our customers in the future. We are also committed to furthering our long history of innovation to expand our product offerings. For example, this quarter, we released our proprietary Alpha-Web filtration media. This new hydraulic technology improves fluid cleanliness up to four times and creates additional value for customers by extending critical component life. In addition to our organic investments, we are working through our M&A pipeline and actively pursuing Life Sciences opportunities with a focus on revolutionary technologies and applications, such as those we acquired through Solaris, Purilogics, and Isolere Bio. Now I'll provide some detail on Q3 sales. Total company sales were $876 million, up 3% from prior year. In Mobile Solutions, total sales were $555 million, roughly flat versus a year ago. Pricing added 9%, and FX was an approximate 3% headwind. Our first-fit businesses continue to perform well, with sales in off-road of $116 million, up 11% year-over-year, and sales in on-road of $38 million, up 5%. These results reflect healthy levels of equipment production rates across all our major geographies. Mobile Solutions aftermarket sales of $401 million were down roughly 3% year-over-year from OE customer inventory drawdowns to more normal levels. Lastly, for Mobile Solutions, an update on China. Sales increased 5% versus 2022, and 14% in constant currency. While this year-over-year growth marks a considerable improvement from what we reported in the Q2, the one thing to note is that last year's Q3 sales were depressed from COVID-19 lockdowns. Overall, China continues to be challenging, given the weaker end market conditions. That said, sheer market size, combined with our world-class technology and high-quality offerings, should result in Donaldson's success in the Chinese market over the long term. Now I'll turn to the Industrial Solutions segment. Industrial sales grew 14% to $262 million. Pricing added 6%, and FX was roughly a 3% headwind. Industrial Filtration Solutions, or IFS, grew 13% to $223 million, driven by dust collection and industrial gases part sales. Aerospace and Defense sales were up 22%, supported by the ongoing strength in the commercial aerospace industry. Now on the Life Sciences segment. Life Sciences sales were $59 million, down 13% year-over-year. Weakness in the overall disk drive market continues to drive the majority of the decrease. However, we are now seeing a flattening and forecasting a slow demand recovery during the second half of calendar 2023. Our food and beverage business remained solid in the quarter, with continued momentum in both new and replacement parts sales. We look forward to continuing to provide updates on all of our businesses within this segment in the future. As we progress through the final quarter of fiscal 2023, we've been extremely pleased with our ability to deliver strong financial results thus far this year while making strides across our strategic initiatives. As such, we are reaffirming our sales and earnings guidance for the full year by tightening our previously provided outlook ranges and remain confident in our achieving our long-term targets laid out at our recent Investor Day. Now I'll turn it over to Scott, who will provide more details on the financials and an update on our outlook for fiscal 2023. Scott? Thanks, Todd. Good morning, everyone. Q3 results reflect another solid quarter for Donaldson, in which our employees delivered for our customers and planted seeds for future profitable growth, laying the groundwork for achieving our longer-term financial and strategic objectives. I thank our employees around the globe for their daily contributions. I will provide color on our outlook for the balance of the year in a few minutes, but first, we'll give more details on the results this quarter. To summarize, sales grew 3% versus 2022, operating income was up 12%, and EPS of $0.76 increased 14% year-over-year. Gross margin was 33.0%, a 150 basis point improvement versus prior year. Similar to the first half of the year, this quarter we saw benefits from our pricing and the stabilization of input cost inflation. Gross margin was down sequentially, as expected, due to an unseasonably strong Q2, driven in part by inventory valuation and the timing of deflation. Overall, Q3 gross margin results were consistent with our internal expectations. Operating expenses as a percentage of sales were 18.8%, slightly above 18.5% a year ago. The deleveraging of operating expenses in the quarter was due to an increase in Life Sciences, investments, and post-COVID-19 hiring. Operating margin was 14.2%, up 120 basis points versus prior year, driven by gross margin improvement. In line with my comments on gross margin, operating margin was down sequentially due to an unseasonably high Q2. I'll discuss segment profitability. Mobile Solutions pre-tax profit margin was 15%, up 70 basis points year-over-year, and Industrial Solutions pre-tax profit margin was 18.8%, up 390 basis points from the prior year. Gross margin expansion was a key driver in both of these segments. On the Life Sciences side, pre-tax profit margin was 0.3% versus 20.6% a year ago. The decline in disk drive sales was the largest driver. However, investments in our pre-revenue acquisitions, including Isolere Bio, also negatively impacted results. We are in the investment phase of these acquisitions and are priming them for future growth. Excluding acquisitions, pre-tax profit margin would have been better by approximately 800 basis points. Turning to a few balance sheet and cash flow statement highlights. Q3 capital expenditures, mainly inclusive of continued capacity expansion investments in North America, were approximately $36 million. Cash conversion in the quarter was 105% versus 49% in 2022. We are now experiencing above average levels of conversion, resulting from inventory-related working capital benefits from the easing of supply chain constraints. In terms of other capital deployment, we acquired Isolere Bio for $62 million and returned $32 million to shareholders, inclusive of $28 million in the form of dividends and $4 million in share repurchase. Our balance sheet is strong, and we end the quarter with a net debt-to-EBITDA ratio of 0.7 times. Moving to our updated fiscal 2023 outlook. First on sales. We expect fiscal 2023 sales to increase between 3% and 5%, the midpoint of which is in line with our previous guidance. This includes pricing of approximately 8% and a negative impact from currency translation of about 4%. As forecasted, as the year has progressed, we have lapped stronger prior pricing actions each quarter, resulting in less of an incremental benefit as we move through the year. We expect this trend to continue in the Q4. For Mobile Solutions, we are anticipating a sales increase of between 2% and 4%, consistent with our prior expectations. On-road and off-road sales are forecast to be up mid-single digits and high single digits, respectively. Aftermarket sales are projected to be up low single digits. For the Industrial Solutions segment, we are increasing the midpoint of our guidance, with sales now expected to increase between 11% and 13%, up from 8%-12% previously. Robust volume growth and pricing, essentially across the entire segment, are driving the improvement. Within Industrial Solutions, IFS sales, strengthened by robust dust collection and industrial gases part sales, are forecast to grow low double-digits, an increase from high single-digits previously. Aerospace and Defense sales are projected to grow mid-teens, up from our previous low double-digit expectation. Within the Life Sciences segment, we are now forecasting a sales decline between 10%-12% versus a decline between 5%-9% previously. The main drivers of the reduced outlook are continued disk drive sales weakness and a change in timing of Solaris or bioprocessing equipment sales. On operating margin. We expect full year operating margin to fall within a range of between 14.4%-14.8%, slightly down from our previous guidance of between 14.6%-15.0%. This is mainly a result of our Life Sciences investments as we focus on scaling our pre-revenue acquisitions. As we have consistently stated, we continue to exercise expense discipline, particularly given the uncertain macro environment. However, we are committed to building for the future through our reinvestments back into the business. The midpoint of our updated operating margin range reflects a 110 basis point increase from the prior year and is driven by gross margin expansion. In terms of EPS, we are maintaining our outlook for the year, but narrowing our adjusted guidance range to between $3.00 and $3.06, from $2.99 and $3.07 previously. The midpoint of this range represents an approximately 13% increase from a record fiscal 2022. On to our balance sheet and cash flow outlook. Cash conversion is forecast in the range of 105%-115%, slightly down from 110%-120%. However, still above our historic averages. Our above average cash conversion this year is driven by a move towards more normalized working capital levels as we increase inventory efficiency through optimization of our processes and as supply chain conditions normalize. Our capital expenditures forecast remains at $115 million-$130 million and is heavily weighted towards growth initiatives, including investments in capacity expansion and tooling and equipment for new products and technology. With respect to other capital allocation priorities, we continue to evaluate the best acquisition opportunities for our Life Sciences business and maintain our long-standing commitment to dividends and share repurchases. Now, I'll turn the call back to Todd. Todd? Thanks, Scott. As we close out another record quarter, I want to thank my Donaldson colleagues around the globe for their dedication and hard work. With this outstanding team in place, the future is bright, and I'm excited about what lies ahead for our company. I spoke earlier about some of the game-changing opportunities we are pursuing in our Life Sciences segment. We are also investing in pursuing growth in our Mobile Solutions and Industrial Solutions segments. For example, in mobile, we are making progress on building our portfolio of alternative power solutions, and in industrial, we are pushing ahead with our goal of increasing our industrial services business by leveraging our Connected Solutions offerings. Underpinning all of our future growth initiatives is Donaldson's commitment to our people, customers, and communities through our purpose of advancing filtration for a cleaner world. To that end, coinciding with our Investor Day in April, we published our 2022 sustainability report, in which we outlined 2030 ESG ambitions. In summary, by fiscal 2030, we are targeting an absolute reduction of Scope 1 and 2 greenhouse gas emissions by 42% from fiscal 2021 baseline. We expect to reach 35% in terms of women in global leadership positions, starting from a January 2023 baseline. We plan to increase charitable giving through the Donaldson Foundation by 25% every four years, giving cumulatively at least $13.5 million, starting from fiscal year 2022. In closing, we look forward to reporting on the progress we are making towards all of our key strategic initiatives and longer-term financial goals in the future. Now, I'll turn the call back to the operator to open the line for questions. As a reminder, if you would like to ask a question, press star, then the number one on your telephone keypad. Your first question today comes from the line of Nathan Jones with Stifel. Your line is open. Good morning, everyone. Good morning, Nathan. Maybe we could just start with a bit more color around gross margins. Obviously, you know, guys talked about 2Q being unseasonably high, but gross margin is a bit lower than maybe I would have expected here with price catching up to cost. Maybe you could talk about, you know, the inputs there. I mean, I assume disk drives is higher gross margin, so it's probably a headwind there. Just where you think once we see all the normalization of price cost and the headwinds out of disk drives, maybe what you're thinking about for gross margins at a normalized level? Yeah. Hi, Nathan, this is Scott. Yeah, we've had kind of an interesting run of gross margins. The Q1 was 33.9%, Q2, 34.5%, and then the Q3 came in at 33%. As you remember, we said at the end of the Q2, we expected Q3 to be down, you know, and it was. There continues to be a lot of things going on in our income statement, you know, with inflation and inventory costing and the pretty significant reduction in inventories that we took this quarter, along with, you know, a decline in disk drive sales. There's really a lot in the soup there, but we landed at 33%. We expect, you know, Q4 to certainly be up from Q3, you know, as things normalize and hopefully, you know, our price-cost situation for the whole world, starts to kind of slow down and balance out a bit. You know, it was a little bit tougher quarter on gross margin. We expected it to come down, and it did. We expect Q4 to be up. That's kind of a high-level summary for you. We're gonna get maybe between 33.5% and 34% for the full year. If I go back a few years, I know you had some capacity issues back in, like, 2019 and 2020, and obviously, COVID's created a lot of noise. We're kind of in the 34%-35% range before that. Is that a reasonable expectation for what the business should be running at for gross margins? Yeah, Nathan, this is Todd. Yes, it is. You know, the one new variable that we have coming in there is obviously all of the investments that we're putting into the Life Sciences activities, which will give us a little bit of a mix pressures. We would believe still 34%-35% is reasonable and where we expect to land. Maybe just one more on those investments in Life Sciences. Can you talk about the magnitude of those, the duration of those? I mean, I would assume that those are likely to continue to step up year-over-year as we go forward, as you continue to invest in those businesses. I mean, like you said, we're not even at them generating any revenue yet. Is there an expectation that this is an investment cycle that lasts a few years for you? Nathan, the way we look at this thing, so far it's actually evolving as we would have expected. We believe that we're gonna give you a bit more information here when we guide full year in about 90 days. We would expect clearly, as we see through the balance of this fiscal year, for it to be all in the investment column for the balance sorry, I said fiscal. For the balance of this calendar year, it'll be all in the investment column. We'll come out with more detail here when we full year guide. Okay. Thanks for taking my questions. Thanks, Nathan. Your next question comes from the line of Brian Drab with William Blair. Your line is open. Morning. I was wondering if you could just start by elaborating a little bit on the timing, this issue of the timing and the bioprocessing equipment, and, you know, when does it ship? When was it expected to ship, et cetera? Yeah, Brian, this is Todd. Three components, right? Solaris is already revenue generating, it's project-based. That is the project type of activities that could go from quarter to quarter, based upon when customers are ready to take shipments. We're actually on plan to meet what was in the full year guide for Solaris's activities and shipments this year. We'll again guide next year here in about 90 days. When you look at the other two, Isolere Bio and Purilogics, you know, that's revenue generating ahead of us. That their revenue today is 0, and so we're planting solid seeds for future growth with both of those activities and both of those businesses, so that's future revenue. We'll give you a little bit more color here next year, or, when we report next, fiscal. Certainly, we would expect that to be more headwinds for the balance of this calendar year. Okay. All right, thanks. In the disk drive business, at the analyst meeting that you had recently, I was, I guess, under the impression that, you know, headwind in this fiscal year, but, you know, normalizing and maybe, I don't know if... I guess I got the impression at least be stable in the next fiscal year. Is that a growth business, do you think, going forward, or is it stable, and then the whole segment starts to grow when we get the Life Sciences, the newer Life Sciences pieces growing? We believe that we're stabilizing now, flattening, if you will. It's been a very difficult run for that business, almost cut in half within this fiscal year. For example, we have taken the necessary cost actions to support the current levels of that business. We're flattening at this point in time. We think we'll start to crawl forward or get slight lift for the balance of this calendar year. It, it will turn into a slight growth business looking forward. Just lastly, I missed it, but what did you say about food and beverage in this most recent period? How did that business do specifically? Yeah, food and beverage did really strong again, continues to do quite well in the portfolio. At this point in time, we're up in local currency, low double digits in the quarter and continuing to expand and really are very happy with our performance. Great. Thanks a lot, Todd. Thanks. Your next question comes from the line of Laurence Alexander with Jefferies. Your line is open. Good morning, this is Dan Rizzo for Laurence. Thank you for taking my question. Just with in regards to China, just given everything that's kind of occurred and is occurring, have your expectations for the region been kind of, I don't know, have they diminished at all, as we look in the next two to three quarters, just given the, I guess, the lack of a strong rebound as of yet? Not at all. Actually, when you look at China and the opportunity for the company, long term, it remains very strong. We continue to win national-based programs, which will continue to gain share within region. I just want to remind everyone that we are in China to support China. We are not a China-based exporter. For example, it's China to support China-based customers, largely nationally now, with technology such as PowerCore. The, you know, the thing that's a bit muted is with China is just simply the economic recovery, obviously. We're experiencing that. Even given the careful outlook on China's base economy, we continue to win programs, which gives us confidence in the long-term direction of China. One of the things you mentioned, I think was labor costs being up. That's except, understandable, but you also mentioned doing more hiring. I was wondering if it's hard to find people now still, given what we're reading with, you know, labor tightness, and if you are gonna be doing significantly more hiring over the next couple of quarters or years or whatever. Within our manufacturing base, if you will, it's a little bit different by region. I would say that within the U.S., it's certainly improved, but not great, not pre-COVID based levels, but certainly improved. Within Europe, it's fine. Asia, it's fine. Latin America, it's strong. Really the headwinds and the concerns, if anything, are U.S.-based. Within salary-based positions, a little bit more careful everywhere, actually. People are just being careful to come on board. We do expect to be able to support the expansions that we have of the strategic plans that we have. We have to work a little bit harder in order to get there, but we're pretty pleased with our progress. Okay. Final question. On a free cash flow conversion, can you just remind us what the long-term target is? I know it was elevated because of all the fluctuations, what should we think about as we model out over the next couple of years? We, you know, we've had kind of unusual cash conversion, as I'm sure you've seen, right? We, we took inventories up by $100 million during COVID to help fight the supply chain and make sure we were living up to our commitments to our customers. Then we got into this year, we said we were gonna take that $100 million out, you know. As of the Q3, our inventory has gone from $502 million down to $449 million. We've made good progress there, and you're starting to see that flow through our cash, our cash conversion this year. If you go to page, I guess, 99 or my slides in the investor deck, we said that our, you know, our longer term average was about 85% on cash flow conversion. Okay. Thank you very much. Yeah, thanks. Thanks, Dan. As a reminder, if you would like to ask a question, press star, then the number one on your telephone keypad. Your next question comes from the line of Rob Mason with Baird. Your line is open. Great, thanks. Todd, when you were commenting on the Mobile Solutions business aftermarket, you talked about the OE dealer channel bringing inventory down to normal levels. Is that activity, destocking activity complete here in the Q3? I'm also, you know, just curious what kind of impact that had on the Q3 aftermarket business as well. What you see across the OE channel, in Mobile Solutions aftermarket, specifically to OE, is a step down in the Q3. Think in terms of certainly teams level being pulled out in the quarter, whereas on an independent channel, you would see that we have growth at the revenue level. Call it low to mid single digits growth on the independent. That means the volume on the independent is slightly down based upon pricing, so you'll see a little bit of a pullback there. That would be the behavior that we would have expected, because they were never able to actually get their stock levels up to where we would have expected them to, and the OEs kind of won out. The OEs are pulling it back down. We would expect that to kind of normalize here as we get through the summer. The independent channel, we feel is that pull-through level is pretty comfortable, at this point. That's helpful. Just... I, I, you know, I'm doing some quick back of the math, or back of the envelope math here, but it looks like for the first fit, Mobile Solutions in the Q4, the revenue would decelerate sequentially. I just wanted to check that. If that's the case, is that, is that a function of just normal seasonality or were there some catch-up shipments in the Q3? Actually, we would see it just kinda being normal seasonality type of activity for us. Very comfortable with the first fit side of production at this point, based upon what we're seeing in backlogs, et cetera. The first fit continues to do quite well. We're happy with it. And that's across all end markets, construction, ag, mining, first fit on the over-the-road trucks. It was the aftermarket that kind of came in a little bit more on the pullback to the OE side this quarter than we would have expected. Sure. Then just finally, a larger question around price. You did take up your price expectations for the full year. I'm just curious, what were the main drivers behind that increase? How do you think about, you know, pricing going forward from here to the extent that you noted, raw material prices are kinda normalized, but to the extent labor is still a pressure, you know, your ability to offset the labor impact if needed? Maybe I'll let Scott start here, with the first part of the question, then I'll jump in for a little additional color on the second half. Hi, Rob, this is Scott. We did take our guide for price up 2%. I mean, part of that is just a refinement of our calculation and our estimate for the year. Part of that is related to the labor comments Todd previously made, and we got to continue to make sure we manage our price and cost, and we're gonna continue to adjust prices, you know, for the next 10 years. You know, if our costs are going up, we have to be compensated for that in the market, and we're gonna pass those prices on. You know, a 2% increase is within a normal range for us, I would say. We continue to push price where appropriate, and we're gonna continue to drive those increases into the market to just make sure we have a reasonable commercial relationship with our customers, and that we treat our suppliers, you know, properly. Yeah. I would say that we've returned to a more normal behaving price, activity across the company, in all regions of the world. I also want to say that we remain very committed, to price cost recovery, and, so we keep an eye on it, which means we would take an out of cycle, action, should that be necessary. Very good. I'll turn it back. Thank you. This concludes our Q&A session for today. I now turn the call back to Tod Carpenter for closing remarks. That concludes the call today. Thanks to everyone who participated, and I look forward to reporting our Q4 results in late August. Have a great rest of the week. Goodbye. This concludes today's call. You may now disconnect.